{"id":"aav9-slc6a1-gene-therapy","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This gene therapy uses an adeno-associated virus 9 (AAV9) vector to deliver the SLC6A1 gene to the brain, where it is expected to restore normal function of the SLC6A1 protein.","oneSentence":"AAV9-mediated delivery of the SLC6A1 gene to the brain","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:51:26.889Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treats Huntington's disease"}]},"trialDetails":[{"nctId":"NCT07173153","phase":"PHASE1, PHASE2","title":"Gene Therapy for SLC6A1 Neurodevelopmental Disorder","status":"ENROLLING_BY_INVITATION","sponsor":"Emily de los Reyes","startDate":"2025-08-25","conditions":"SLC6A1","enrollment":1}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"AAV9.SLC6A1 Gene Therapy","genericName":"AAV9.SLC6A1 Gene Therapy","companyName":"Emily de los Reyes","companyId":"emily-de-los-reyes","modality":"Biologic","firstApprovalDate":"","aiSummary":"AAV9-mediated delivery of the SLC6A1 gene to the brain Used for Treats Huntington's disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}